Department of Haematology, Jeffrey Cheah Biomedical Centre, University of Cambridge, UK.
Cambridge Stem Cell Institute, University of Cambridge, UK.
Mol Oncol. 2023 Dec;17(12):2493-2506. doi: 10.1002/1878-0261.13544. Epub 2023 Nov 2.
Leukaemia stem cells (LSCs) are the critical seed for the growth of haematological malignancies, driving the clonal expansion that enables disease initiation, relapse and often resistance. Specifically, they display inherent phenotypic and epigenetic plasticity resulting in complex heterogenic diseases. In this review, we discuss the key principles of deregulation of epigenetic processes that shape this disease evolution. We consider measures to define and quantify clonal heterogeneity, combining information from recent studies assessing mutational, transcriptional and epigenetic landscapes at single cell resolution in myeloid neoplasms (MN). We highlight the importance of integrating epigenetic and genetic information to better understand inter- and intra-patient heterogeneity and discuss how this understanding further informs evolution and progression trajectories and subsequent clinical response in MN. Under this topic, we also discuss efforts to identify mechanisms of resistance, by longitudinal analyses of patient samples. Finally, we highlight how we might target these aberrant epigenetic processes for better therapeutic outcomes and to potentially eradicate LSCs.
白血病干细胞(LSCs)是血液恶性肿瘤生长的关键种子,驱动着克隆扩增,从而使疾病的发生、复发和耐药成为可能。具体来说,它们表现出内在的表型和表观遗传可塑性,导致复杂的异质性疾病。在这篇综述中,我们讨论了导致这种疾病演变的表观遗传过程失调的关键原则。我们考虑了定义和量化克隆异质性的措施,将来自最近的研究的信息结合起来,这些研究在髓系肿瘤(MN)中以单细胞分辨率评估突变、转录和表观遗传景观。我们强调了整合表观遗传和遗传信息的重要性,以更好地理解患者间和患者内的异质性,并讨论这种理解如何进一步告知 MN 中的进化和进展轨迹以及随后的临床反应。在这个主题下,我们还讨论了通过对患者样本进行纵向分析来识别耐药机制的努力。最后,我们强调了如何针对这些异常的表观遗传过程,以获得更好的治疗效果,并可能根除 LSCs。